Active, not recruitingPhase 3NCT05809531
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Studying C3 glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Intervention
- Pegcetacoplan(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Academic Medical Research Institute (01034), Los Angeles, California, United States
- Children's Hospital Colorado (01037), Aurora, Colorado, United States
- University of Florida, Department of Pediatric Nephrology (01010), Gainesville, Florida, United States
- Emory Investigational Drug Service (01021), Atlanta, Georgia, United States
- University of Iowa Hospital and Clinics (01030), Iowa City, Iowa, United States
- University of Michigan Hospital (01008), Ann Arbor, Michigan, United States
- Hackensack Meridian Health (01036), Hackensack, New Jersey, United States
- Cohen Children Hospital, Pediatric Pharmacy (01022), Hyde Park, New York, United States
- Columbia Nephrology (01039), New York, New York, United States
- Oregon Health & Science Univ., Dept. Pediatrics (01038), Portland, Oregon, United States
- Northeast Clinical Research Center LLC (01009), Bethlehem, Pennsylvania, United States
- Texas Children's Hospital (01027), Houston, Texas, United States
- Hospital Privado-Universitario de Cordoba (54004), Córdoba, Argentina
- Clinica Privada Velez Sarsfield (54007), Córdoba, Argentina
- Kidney Trials Unit, Princess Alexandra Hospital (61007), Woolloongab, Queensland, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05809531 on ClinicalTrials.govOther trials for C3 glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06209736Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNOmeros Corporation
- RECRUITINGPHASE2NCT04183101Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyRegion Skane
- RECRUITINGPHASE3NCT03955445Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNNovartis Pharmaceuticals